What Levera Treats: Main Uses and Benefits

Levera (Levetiracetam) is an antiepileptic drug that supports the management of three major categories of epileptic seizures. Its use is associated with supporting stability against heightened neurological activity, thereby helping to reduce the frequency and severity of episodes and supporting patient stability.

Levetiracetam is commonly used alone and in combination with other medications to assist with managing focal-onset seizures (which involve one part of the brain). It is also generally utilized as adjunctive therapy for myoclonic seizures and primary generalized tonic-clonic seizures. The use of this medication contributes to easing symptoms associated with acute or episodic changes.

“The treatment may assist with maintaining functional stability during periods where these epileptic events might otherwise interfere with daily comfort.”

The medication is applicable in clinical settings that involve acute or disruptive symptom patterns, particularly when used as a single agent (monotherapy) for newly diagnosed focal seizures or alongside other medications (adjunctive therapy) for more complex or difficult-to-control cases. It helps address symptom clusters that may appear suddenly in generalized epilepsy, supporting the patient during difficult episodes by helping to ease distress.

---

Quick Fact: Supportive Management for Recurrent Seizures The medication plays a role in managing symptoms related to increased neurological activity and may assist with maintaining day-to-day comfort during symptomatic periods.

Regulatory References

1. Levetiracetam: MedlinePlus Drug Information

Who Can and Cannot Use Levetiracetam (Levera) — Official Regulatory Information

Official government labeling strictly defines eligibility for Levetiracetam based on three core areas: absolute exclusion, age, and organ function.

Classification	Population or Condition
Absolute Contraindication	Known hypersensitivity to levetiracetam or any inactive ingredients/excipients.
Use Restricted (Renal)	Patients with renal impairment (kidney disease) and older adults (due to probable reduced renal function) require mandatory dose adjustment based on creatinine clearance.
Use Restricted (Hepatic)	Patients with severe hepatic impairment often require a dose reduction, especially if associated with reduced renal function.

Age-Related Eligibility:

• Monotherapy is approved for adolescents and adults starting at 16 years of age. Efficacy in younger children for monotherapy has not been established.
• Adjunctive Therapy is approved for infants starting at 1 month of age for partial-onset seizures, though the minimum age varies for other seizure types.

Pregnancy and Lactation Status:

The medicine is classified as Pregnancy Category C. Use during pregnancy is permitted only if the potential benefit justifies the potential risk. Levetiracetam is excreted into breast milk, and manufacturers often recommend against breastfeeding due to the potential for adverse reactions in the infant.

Interactions with other medicines and products

Official regulatory information regarding Levetiracetam (Levera) interactions indicates a generally low potential for pharmacokinetic drug-drug interactions. This characteristic is supported by the drug's minimal metabolism through the hepatic Cytochrome P450 enzyme system.

Documented Interaction Categories

The most clinically significant documented interactions involve specific medicines that necessitate close monitoring or restriction of co-administration.

Interacting Product/Category	Official Interaction Description	Regulatory Constraint
Methotrexate	Levetiracetam can decrease methotrexate clearance, leading to increased and prolonged plasma concentrations.	Mandatory Monitoring of plasma levels and Dose Adjustment of both medicines required.
Macrogol (Laxatives)	May potentially decrease the efficacy of Levetiracetam by removing the drug from the gastrointestinal tract.	Concomitant Use Generally Not Recommended.
Other Antiepileptics	Pharmacokinetic interactions are considered unlikely to be clinically significant.	No major constraint; no significant alteration to plasma levels observed.
Oral Contraceptives	Co-administration did not influence the pharmacokinetics of the oral contraceptive components.	No constraint; no significant interaction observed.

Profile Summary

The regulatory profile emphasizes that Levetiracetam does not require major adjustments when co-administered with most enzyme-inducing or enzyme-inhibiting antiepileptic drugs. The primary interaction constraints are tied to the specific combination with Methotrexate, demanding precise monitoring and dosage changes, and with Macrogol, which is advised against due to potential reduced effectiveness.

Modulating Key Synaptic Communication

This drug's core action involves binding with high affinity to Synaptic Vesicle Protein 2A ( SV2A), a protein located on the membranes of presynaptic vesicles in nerve cells that store and release chemical messengers (neurotransmitters).

By modulating SV2A function, the drug influences the stability of neurotransmitter release into the synaptic cleft, an essential step in nerve communication. This primary mechanism limits the subsequent release of both excitatory (glutamate) and inhibitory ( GABA) neurotransmitters, particularly during periods of high-frequency electrical activity.

Regulating Neuronal Hyperexcitability

The SV2A modulation, coupled with a subtle influence on certain high-voltage activated calcium channels (Cav1.2), contributes to a reduction in excessive, rapid electrical signaling across neuronal networks. This dual mechanistic approach limits the overall level of neuronal hypersynchronization—where large groups of neurons fire uncontrollably at the same time—which is the physiological consequence of its action on neuronal electrical activity.

How Levera is Used: Official Administration Guidelines

Levera (levetiracetam) is administered according to established protocols and label-based guidelines.

Dosing and Frequency

Formulation Type	Frequency	Adult Starting/Maximum Daily Dose
Immediate-Release (IR) Oral	Twice daily (BID)	Initial: 1000 mg (500 mg BID) / Maximum: 3000 mg (1500 mg BID)
Extended-Release (XR) Oral	Once daily (QD)	Initial: 1000 mg / Maximum: 3000 mg

• Titration Schedule: The dose is typically initiated at a low level and increased by 1000 mg/day increments every two weeks until the final required daily dose is reached.

Administration Instructions

• Oral Intake: Levetiracetam oral tablets and solution can be taken with or without food. Immediate-release tablets are generally swallowed whole. Extended-release tablets must be swallowed whole and must not be crushed or chewed.
• Intravenous (IV) Use: The IV solution is used as a temporary alternative when oral administration is not feasible. The total daily dosage and frequency should be equivalent to the oral dosage. IV administration requires the dose to be given as a 15-minute infusion.
• Pediatric and Special Populations: Dosing for children is weight-based (mg/kg). For older adults and patients with impaired renal function, the dose is adjusted based on estimated Creatinine Clearance, as the drug is primarily eliminated by the kidneys. For patients undergoing dialysis, a supplemental dose is required after each dialysis session.

Research Evidence / Overview of Studies for Levera

Evidence for Use in Focal-Onset Seizures

Clinical evaluation for the use of Levetiracetam in managing focal-onset seizures was established through multiple short-term, randomized, double-blind, placebo-controlled trials (RCTs). These studies primarily examined outcomes related to episodic changes by monitoring the percent change in weekly focal seizure frequency. Controlled trials reported measurements detailing the changes in seizure frequency that were observed during the short-term evaluation phase in populations that often included patients with refractory (difficult-to-control) seizures.

Evidence for Use in Myoclonic Seizures and Primary Generalized Tonic-Clonic Seizures

Research evaluating the medication for myoclonic seizures and Primary Generalized Tonic-Clonic (PGTC) seizures was also based on key randomized, double-blind, placebo-controlled trials. For myoclonic seizures, studies examined the change in the frequency of days per week with seizures in adolescents and adults (12 years and older). For PGTC seizures, studies monitored the percent change in weekly seizure frequency in patients 4 years of age and older.

Long-Term Studies and Research Gaps

Beyond the initial short-term controlled trials, evidence related to prolonged use is derived mainly from long-term open-label extension studies and observational settings. These studies tracked the rate at which patients remained on the medication (retention rate). A known limitation across the evidence landscape is that follow-up durations were limited in the pivotal controlled phases, meaning long-term effects are not fully established by this type of research. Data for specific pediatric subgroups, such as children under 12 for myoclonic seizures, remain insufficient, and subgroup findings are uncertain due to modest sample sizes.

Key Studies & References Efficacy and safety of levetiracetam as adjunctive therapy for refractory focal epilepsy (a key phase III randomized controlled trial for partial-onset seizures)

Common questions about Levera (FAQ)

---

Q: What condition is Levera primarily prescribed for?

Levera is an antiepileptic medicine, meaning it is used to treat epileptic seizures. Official information states it is primarily indicated as a treatment for partial-onset seizures, myoclonic seizures, and Primary Generalized Tonic-Clonic seizures.

---

Q: What are the benefits of taking Levera?

Clinical studies indicate that Levera helps reduce the frequency of epileptic seizures. As an add-on therapy, research shows it helps to stabilize brain activity, which leads to a reduction in weekly seizure occurrences compared to taking an inactive pill (placebo).

---

Q: What are the most common side effects of Levera that people report?

Official information lists sleepiness (somnolence) and weakness (asthenia) as very common side effects in adults. In children, common reactions include fatigue, irritability, and aggression. Concerns about side effects are typically addressed by a healthcare professional.

---

Q: What are the signs of a severe allergic reaction to Levera?

The medicine carries a warning for rare but serious allergic and skin reactions. These can include severe rashes like Stevens-Johnson Syndrome (SJS) and signs of anaphylaxis or angioedema, such as swelling of the face, lips, tongue, or throat, and difficulty breathing. These symptoms require immediate attention from a medical professional.

---

Q: What if I vomit shortly after taking my Levera dose?

Regulatory documents do not contain specific instructions for vomiting shortly after a dose. Because maintaining consistent medicine levels is critical for seizure control, it is necessary to contact the prescribing healthcare provider for guidance. Guidance on whether to take another dose or wait for the next scheduled dose must come from the healthcare provider.

---

Q: What are the potential effects of Levera on concentration and memory?

Levera is known to cause Central Nervous System (CNS) side effects, such as sleepiness, dizziness, and fatigue. These effects can, in turn, affect alertness and the ability to think clearly. Due to these potential effects, caution is advised when performing activities requiring full mental focus.

---

Q: Does Levera have a risk of dependence?

No, Levera (levetiracetam) is not classified as a controlled substance by the U.S. Drug Enforcement Administration (DEA). This means it is not categorized as a medicine with a significant potential for abuse or physical dependence.

---

Q: Is Levera considered a controlled substance?

No, levetiracetam (Levera) is not classified as a controlled substance by regulatory bodies. It is not listed as having a significant potential for abuse or dependence, unlike some other antiepileptic medications.

---

Q: How quickly does Levera start working after the first dose?

While the medicine is absorbed relatively quickly after the first dose, the full benefits in terms of seizure reduction are often observed over time as the dosage is gradually adjusted, or 'titrated.' Physicians start at a low dose and increase it to find the best therapeutic level.

---

Q: Is it normal to feel tired when first starting Levera?

Yes, it is common to experience sleepiness (somnolence) and fatigue (asthenia) when initiating treatment. These are listed as very common side effects in the official product information and may be more noticeable at the beginning of treatment or following a dose increase.

---

Q: Can Levera affect mood or cause emotional changes?

Yes, official warnings indicate that Levera may cause behavioral changes and psychotic symptoms. These can include aggression, irritability, anger, or suicidal thoughts. Monitoring for unusual changes in mood or behavior is part of the treatment protocol.

---

Q: Does Levera interact with common over-the-counter pain relievers?

Regulatory studies generally found a low likelihood of interaction with drugs that affect liver enzymes. However, official information does not specifically list common over-the-counter pain relievers as being tested. Regulatory advice states that patients should inform their healthcare providers about all medicines they are taking.

---

Q: Are there any specific vitamins or supplements that interact with Levera?

Official regulatory information does not specifically mention interactions with vitamins or common supplements. The medicine is noted for its low potential for pharmacokinetic interactions. However, it is standard practice to consult a physician before making changes to supplement intake.

---

Q: What happens if I accidentally miss a dose of Levera?

The official product instructions do not provide a detailed, standardized missed dose plan. General advice for missed doses of a twice-daily medication is often to take it when remembered. However, guidance for a specific missed dose must be provided by the prescriber to maintain proper seizure control.

---

Q: Does Levera cause weight gain or loss?

Loss of appetite (Anorexia) is listed as a common side effect in the official safety profile. Overall, studies suggest the drug is generally considered weight-neutral, meaning significant changes in body weight are not a widely expected side effect.

---

Q: Can Levera affect my sleep patterns?

Yes, the regulatory label lists somnolence (sleepiness) as a very common side effect. This may lead to daytime drowsiness. Any significant change in sleep patterns or excessive drowsiness should be discussed with a healthcare provider.

---

Q: Does Levera cause any long-term health problems?

The initial, short-term controlled studies that led to the drug's approval had limited follow-up periods. Therefore, information on the full long-term effects is primarily gathered from subsequent open-label extension studies and ongoing safety monitoring efforts.

---

Q: Does age affect how Levera works?

Age does affect the dosing requirements. Dosing for children is based on their weight ( mg/kg). Older adults may need dose adjustments because the medicine is mainly cleared by the kidneys, and renal function can decrease with age.

---

Q: Do I need to get blood tests done regularly while taking Levera?

The regulatory information indicates a risk of Hematologic Abnormalities (changes in blood cell counts), which may require monitoring in certain patients. Additionally, mandatory blood monitoring may be required when co-administering with the cancer drug methotrexate.

---

Q: Can Levera make my existing mental health issues worse?

Official warnings include the potential for new or worsened behavioral abnormalities and psychotic symptoms. Pre-existing conditions should be discussed with a physician, as close monitoring for changes in mood or behavior is typically recommended.

---

Q: Why is it important to take Levera at the same time every day?

Taking the medicine at consistent times ensures that a stable level of the drug remains in the bloodstream throughout the day. This consistent concentration is critical for achieving optimal seizure control, which is the overall goal of the drug's prescribed regimen.

---

Q: Can Levera affect driving ability?

Yes, the official label advises that the medicine can cause sleepiness and fatigue. The warning advises against driving or operating complex machinery until a patient understands how the medicine affects their alertness.

---

Q: Are headaches a common side effect when starting Levera?

Headache is listed in the official documents as a very common adverse reaction, meaning it is reported in 10% or more of patients. Although the label does not specify the exact timing, the high frequency suggests it can certainly occur when treatment is initiated.

---

Q: How long does the effect of a single dose of Levera last?

The drug is designed to maintain therapeutic blood levels between doses. This is reflected in the dosing schedule: the immediate-release form is prescribed twice daily, and this frequency ensures continuous seizure protection throughout a 24-hour period.

---

Q: Are there any known interactions between Levera and herbal remedies?

Official regulatory documents do not specify interactions between Levera and particular herbal or traditional remedies. It is generally advised to provide a full list of all co-administered products, including herbal remedies, to the healthcare provider.

---

Q: Does the time of day I take Levera matter for effectiveness?

Consistency in timing is essential for effectiveness. The dose is prescribed to be taken at specific, regular intervals (e.g., morning and evening for twice-daily dosing) to maintain a stable drug concentration. Taking the dose around the same time each day helps ensure continuous seizure control.

The storage and disposal of Levetiracetam (Levera) must adhere to official regulatory requirements to ensure product stability and safety.

Storage Requirements

• Temperature: Store at Controlled Room Temperature (CRT), typically defined as 20 C to 25 C (68 F to 77 F), with excursions permitted up to 30 C (86 F).
• Protection: The medicine must be protected from heat, moisture, and direct light, and the oral solution must not be frozen.
• Container: The product must be stored in its original, tightly closed container.
• Child Safety: It is mandatory to keep this medicine out of the reach and sight of children.

Stability and Disposal

• Oral Solution Stability: Once the bottle is opened, the oral solution has a specific in-use stability period (e.g., seven months) and should be used within that time frame.
• Disposal: Unused or expired Levetiracetam products must be disposed of in accordance with local, regional, and national regulations. The labeling instructs that the product should not be disposed of via wastewater to prevent environmental contamination.